The Staircase Phenomenon Implications on Neuromuscular Block Monitoring
The Staircase Phenomenon and His Implications on Neuromuscular Block Monitoring During General Anesthesia
1 other identifier
interventional
50
1 country
1
Brief Summary
The staircase phenomenon could have repercussions on the onset and recovery time following administration of a neuromuscular blocking agent. The investigators aim to assess the magnitude of the staircase phenomenon and its impact on various aspects of neuromuscular blockade with a randomized controlled double blind trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 25, 2017
CompletedFirst Posted
Study publicly available on registry
May 10, 2017
CompletedMay 10, 2017
May 1, 2017
1.1 years
April 25, 2017
May 5, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Difference in Block Onset time difference (seconds)
Onset time is the time between Train of Four (TOF) at the moment of injection of neuromuscular blocking drug and the minimum value reached (onset of neuromuscular block)
rom 0 seconds up to 240 seconds after neuromuscular block administration at the beginning of surgery. Time frame is the duration of general anesthesia before, during and after surgery (up to 4 hours).
Secondary Outcomes (11)
Difference in time until recovery of a TOF ratio (TOFr) of 0.9
From administration of neuromuscular blocking drug until spontaneous reversal (up to 4 hours). Time frame is the duration of general anesthesia before, during and after surgery (up to 4 hours).
Difference in TOFr 0.9 Normalized
From administration of neuromuscular blocking drug until spontaneous reversal at this specified point (up to 4 hours). Time frame is the duration of general anesthesia before, during and after surgery (up to 4 hours).
Difference in time until recovery of 25% of maximum twitch height ot T1 stimulus (DUR25)
From administration of neuromuscular blocking drug until spontaneous reversal at this specified point (up to 4 hours). Time frame is the duration of general anesthesia before, during and after surgery.(up to 4 hours)
Time between 25% and 75% of maximum twitch height recovery of T1 stimulus
From administration of neuromuscular blocking drug until spontaneous reversal (up to 4 hours). Time frame is the duration of general anesthesia before, during and after surgery (up to 4 hours).
Difference between first stimulus of Train-of-Four ratio at baseline
Single measurement of muscle response after calibration procedure at the beginning of data recording after randomization. It is not a time-to-event variable
- +6 more secondary outcomes
Study Arms (2)
Tetanic Group
EXPERIMENTALA Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
Control Group
NO INTERVENTIONConventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
Interventions
Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
Eligibility Criteria
You may qualify if:
- ASA (American Society of Anesthesiology surgical risk scale) grade I - II
- Surgery not involving airway performed under general anaesthesia with neuromuscular blocker
You may not qualify if:
- Pregnancy
- BMI (Body Mass Idex) \> 35 Kg/m2
- Anticipated difficult airway
- Chronic kidney or hepatic failure
- Neuromuscular disease
- Medication that has known interactions with neuromuscular blockers
- Hemodynamic failure
- Anticipated large blood loss
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitario La Fe
Valencia, Spain
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Anesthesiology Consultant
Study Record Dates
First Submitted
April 25, 2017
First Posted
May 10, 2017
Study Start
February 1, 2013
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
May 10, 2017
Record last verified: 2017-05